The pharmacogenomic and immune landscape of snoRNAs in human cancers

IF 9.1 1区医学 Q1 ONCOLOGY

Cancer letters Pub Date : 2024-10-18 DOI:10.1016/j.canlet.2024.217304

Runhao Wang , Chengxuan Chen , Yuan Liu , Mei Luo , Jingwen Yang , Yamei Chen , Lifei Ma , Liuqing Yang , Chunru Lin , Lixia Diao , Leng Han

{"title":"The pharmacogenomic and immune landscape of snoRNAs in human cancers","authors":"Runhao Wang , Chengxuan Chen , Yuan Liu , Mei Luo , Jingwen Yang , Yamei Chen , Lifei Ma , Liuqing Yang , Chunru Lin , Lixia Diao , Leng Han","doi":"10.1016/j.canlet.2024.217304","DOIUrl":null,"url":null,"abstract":"<div><div>Small nucleolar RNAs (snoRNAs) are a class of non-coding RNAs primarily known for their role in the chemical modification of other RNAs. Recent studies suggested that snoRNAs may play a broader role in anti-cancer treatments such as targeted therapies and immunotherapies. Despite these insights, the comprehensive landscape of snoRNA associations with drug response and immunotherapy outcomes remains unexplored. In this study, we identified 79,448 and 75,185 associations between snoRNAs and drug response using data from VAEN and CancerRxTissue, respectively. Additionally, we discovered 29,199 associations between snoRNAs and immune checkpoint genes and 47,194 associations between snoRNAs and immune cell infiltrations. Sixteen snoRNAs were significantly correlated with immunotherapy objective response rate (ORR), and 92 snoRNAs showed significantly differential expression between cancers with high and low ORR. Furthermore, we identified 17 snoRNAs with significantly differential expression between cancer types with high and low immune-related adverse event (irAE) reporting odds ratio (ROR). Several snoRNAs, such as SNORD92, and SNORD83B, may represent promising biomarkers or therapeutic targets that needs further investigation. To facilitate further research, we developed a user-friendly portal, Pharmacogenomic and Immune Landscape of SnoRNA (PISNO, <span><span>https://hanlaboratory.com/PISNO/</span><svg><path></path></svg></span>), enabling researchers to visualize, browse, and download multi-dimensional data. This study highlights the potential of snoRNAs as biomarkers or therapeutic targets, paving the way for more effective and personalized anti-cancer treatments.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"605 ","pages":"Article 217304"},"PeriodicalIF":9.1000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383524006992","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Small nucleolar RNAs (snoRNAs) are a class of non-coding RNAs primarily known for their role in the chemical modification of other RNAs. Recent studies suggested that snoRNAs may play a broader role in anti-cancer treatments such as targeted therapies and immunotherapies. Despite these insights, the comprehensive landscape of snoRNA associations with drug response and immunotherapy outcomes remains unexplored. In this study, we identified 79,448 and 75,185 associations between snoRNAs and drug response using data from VAEN and CancerRxTissue, respectively. Additionally, we discovered 29,199 associations between snoRNAs and immune checkpoint genes and 47,194 associations between snoRNAs and immune cell infiltrations. Sixteen snoRNAs were significantly correlated with immunotherapy objective response rate (ORR), and 92 snoRNAs showed significantly differential expression between cancers with high and low ORR. Furthermore, we identified 17 snoRNAs with significantly differential expression between cancer types with high and low immune-related adverse event (irAE) reporting odds ratio (ROR). Several snoRNAs, such as SNORD92, and SNORD83B, may represent promising biomarkers or therapeutic targets that needs further investigation. To facilitate further research, we developed a user-friendly portal, Pharmacogenomic and Immune Landscape of SnoRNA (PISNO, https://hanlaboratory.com/PISNO/), enabling researchers to visualize, browse, and download multi-dimensional data. This study highlights the potential of snoRNAs as biomarkers or therapeutic targets, paving the way for more effective and personalized anti-cancer treatments.

查看原文本刊更多论文

人类癌症中 snoRNAs 的药物基因组学和免疫格局。

小核RNA（snoRNA）是一类非编码RNA，主要作用是对其他RNA进行化学修饰。最近的研究表明，snoRNA 在靶向疗法和免疫疗法等抗癌治疗中可能发挥更广泛的作用。尽管有了这些见解，但 snoRNA 与药物反应和免疫疗法结果的全面关联情况仍有待探索。在这项研究中，我们利用 VAEN 和 CancerRxTissue 的数据，分别发现了 79,448 和 75,185 个 snoRNA 与药物反应之间的关联。此外，我们还发现了 29,199 个 snoRNA 与免疫检查点基因之间的关联，以及 47,194 个 snoRNA 与免疫细胞浸润之间的关联。有 16 个 snoRNA 与免疫疗法客观反应率 (ORR) 显著相关，92 个 snoRNA 在 ORR 高和 ORR 低的癌症之间有明显的表达差异。此外，我们还发现 17 个 snoRNA 在免疫相关不良事件（irAE）报告几率（ROR）高和低的癌症类型之间有明显的表达差异。SNORD92 和 SNORD83B 等几个 snoRNA 可能是有前景的生物标记物或治疗靶点，需要进一步研究。为了促进进一步研究，我们开发了一个用户友好型门户网站--SnoRNA的药物基因组学和免疫景观（PISNO，https://hanlaboratory.com/PISNO/），使研究人员能够可视化、浏览和下载多维数据。这项研究凸显了 SnoRNA 作为生物标记物或治疗靶点的潜力，为更有效、更个性化的抗癌治疗铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer letters 医学-肿瘤学

CiteScore

17.70

自引率

2.10%

发文量

427

审稿时长

15 days

期刊介绍： Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research. Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy. By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.